Literature DB >> 10092811

Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.

J Bilsborough1, A Van Pel, C Uyttenhove, T Boon, B J Van den Eynde.   

Abstract

Murine mastocytoma P815 induces CTL responses against at least four distinct Ags (AB, C, D, and E). Recent studies have shown that the main component of the CTL response against the P815 tumor is targeted against Ags P815AB and P815E. The gene P1A has been well characterized. It encodes the P815AB Ag in the form of a nonameric peptide containing two epitopes, P815A and P815B, which are recognized by different CTLs. Here, we report the identification of the P815E Ag. Using a cDNA library derived from tumor P815, we identified the gene coding for P815E. We also characterized the antigenic peptide that anti-P815E CTLs recognize on the MHC class I molecule H-2Kd. The P815E Ag results from a mutation within an ubiquitously expressed gene encoding methionine sulfoxide reductase, an enzyme that is believed to be important in the protection of proteins against the by-products of aerobic metabolism. Surprisingly, immunizing mice i.p. with syngeneic tumor cells (L1210) that were constructed to express B7-1 and P815E did not induce resistance against live P815, even though a strong anti-P815E CTL response was observed with splenocytes from immunized animals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10092811

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

Review 1.  The redox basis of epigenetic modifications: from mechanisms to functional consequences.

Authors:  Anthony R Cyr; Frederick E Domann
Journal:  Antioxid Redox Signal       Date:  2011-02-05       Impact factor: 8.401

2.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

3.  Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells.

Authors:  Aurélie Hanoteau; Coralie Henin; David Svec; Charlotte Bisilliat Donnet; Sébastien Denanglaire; Didier Colau; Pedro Romero; Oberdan Leo; Benoit Van den Eynde; Muriel Moser
Journal:  Oncoimmunology       Date:  2017-05-11       Impact factor: 8.110

4.  Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

Authors:  Pawel Mroz; Fatma Vatansever; Angelika Muchowicz; Michael R Hamblin
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

5.  Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.

Authors:  Anil Shanker; Michel Buferne; Anne-Marie Schmitt-Verhulst
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

6.  Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.

Authors:  Maria Grazia Ruocco; Karsten A Pilones; Noriko Kawashima; Michael Cammer; Julie Huang; James S Babb; Mengling Liu; Silvia C Formenti; Michael L Dustin; Sandra Demaria
Journal:  J Clin Invest       Date:  2012-09-04       Impact factor: 14.808

7.  T-cell clonotypes in cancer.

Authors:  Per Thor Straten; David Schrama; Mads Hald Andersen; Jürgen C Becker
Journal:  J Transl Med       Date:  2004-04-08       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.